2023 World Conference on Lung Cancer (Posters)-P2.30. Assessing the Impact of Using Disease-Specific Novel Value Elements on Cost-Effectiveness Results in Lung Cancer

Pdf Summary

A study presented at the World Conference of Lung Cancer analyzed the impact of using disease-specific novel value elements on the cost-effectiveness of nivolumab plus ipilimumab (NIVO IPI) compared to platinum doublet chemotherapy (chemo) as a first-line treatment for metastatic non-small cell lung cancer (mNSCLC) in the United Kingdom (UK).<br /><br />The study found that incorporating novel value elements estimated from mNSCLC-specific data increased the incremental quality-adjusted life years (QALYs) of NIVO IPI compared to chemo by 15%, compared to using estimates from non-specific data. Using non-specific data underestimated the potential benefit of NIVO IPI.<br /><br />The objective of the study was to assess the impact of disease-specific novel value elements on cost-effectiveness results. Cost-effectiveness analyses (CEAs) are performed to compare new interventions with current standard of care and determine their value. In recent years, CEAs have included novel elements of value such as adherence-improving factors, scientific spill over, equity, fear of contagion, and more. However, these elements have often been estimated from data outside the specific disease area, limiting interpretation of results.<br /><br />The study used a targeted literature review to identify novel value elements estimated from mNSCLC-specific data. It also leveraged a previous Canadian CEA for second-line mNSCLC to inform elements estimated from non-specific data. The cost-effectiveness analysis model used a partitioned survival model with three health states and a lifetime horizon of 25 years.<br /><br />The findings showed that incorporating mNSCLC-specific novel value elements increased the incremental QALYs and incremental costs of NIVO IPI versus chemo. The net monetary benefit (NMB) for NIVO IPI versus chemo at a UK willingness-to-pay threshold was significantly different when using mNSCLC-specific data.<br /><br />The study concluded that further research should be conducted to identify and quantify disease-specific novel value elements to fully understand the potential economic value of new therapies.<br /><br />This study was supported by Bristol Myers Squibb, and all authors contributed to and approved the presentation.

Asset Subtitle

Yong Yuan

Meta Tag

Speaker Yong Yuan

Topic Global Health, Health Services & Health Economics: Health Economics

Keywords

World Conference of Lung Cancer

disease-specific novel value elements

cost-effectiveness

nivolumab plus ipilimumab

platinum doublet chemotherapy

metastatic non-small cell lung cancer

United Kingdom

quality-adjusted life years

incremental costs

net monetary benefit